Clozapine exposure and the impact of smoking and gender: A population pharmacokinetic study

Wenzie Ng, Hiroyuki Uchida, Zahinoor Ismail, David C. Mamo, Tarek K. Rajji, Gary Remington, Beth Sproule, Bruce G. Pollock, Benoit H. Mulsant, Robert R. Bies

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The primary objective of this study was to evaluate the magnitude and variability of concentration exposure to clozapine and norclozapine in a real-world clinical setting, with a focus on smoking status, using population pharmacokinetic methodologies. A retrospective review of plasma clozapine and norclozapine concentrations taken from inpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007 was conducted. A nonlinear mixed-effects model was developed using NONMEM, including age, gender, weight, smoking status, and dosage formulation as covariates. Pharmacokinetic parameters and interindividual and residual variabilities were estimated with 1- and 2-compartment models. A total of 519 plasma clozapine concentrations from 197 patients (138 males; mean ± SD age, 38 ± 13 years; schizophrenia spectrum disorder 98.2%) were included for the analysis. A 1-compartment model with first-order absorption and elimination best described the data. Apparent volume of distribution was fixed to a previously reported value in the literature of 7 L/kg.The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively). For clozapine, smokers and males showed increased oral clearance by 6.0 and 4.5 L/h, respectively. For norclozapine, smokers and male gender were associated with an increased oral clearance of 11.3 and 7.6 L/h, respectively. The formulation of clozapine administered had an impact on the absorption rate with a Ka of 0.14/h for tablet and 10.3/h for the suspension form.The data suggest that smoking and male gender are associated with lower exposure to clozapine and norclozapine due to the higher oral clearance. These findings may account for some of the variability in clozapine exposure and have important implications for individualized drug dosing and therapeutic drug monitoring.

Original languageEnglish
Pages (from-to)360-366
Number of pages7
JournalTherapeutic Drug Monitoring
Volume31
Issue number3
DOIs
Publication statusPublished - 2009 Jun
Externally publishedYes

Fingerprint

norclozapine
Clozapine
Pharmacokinetics
Smoking
Population
Drug Monitoring
Tablets
Inpatients
Schizophrenia
Suspensions
Mental Health
Weights and Measures

Keywords

  • Clozapine
  • Gender
  • Nonlinear mixed-effect model
  • Population pharmacokinetics
  • Smoking

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Clozapine exposure and the impact of smoking and gender : A population pharmacokinetic study. / Ng, Wenzie; Uchida, Hiroyuki; Ismail, Zahinoor; Mamo, David C.; Rajji, Tarek K.; Remington, Gary; Sproule, Beth; Pollock, Bruce G.; Mulsant, Benoit H.; Bies, Robert R.

In: Therapeutic Drug Monitoring, Vol. 31, No. 3, 06.2009, p. 360-366.

Research output: Contribution to journalArticle

Ng, W, Uchida, H, Ismail, Z, Mamo, DC, Rajji, TK, Remington, G, Sproule, B, Pollock, BG, Mulsant, BH & Bies, RR 2009, 'Clozapine exposure and the impact of smoking and gender: A population pharmacokinetic study', Therapeutic Drug Monitoring, vol. 31, no. 3, pp. 360-366. https://doi.org/10.1097/FTD.0b013e31819c7037
Ng, Wenzie ; Uchida, Hiroyuki ; Ismail, Zahinoor ; Mamo, David C. ; Rajji, Tarek K. ; Remington, Gary ; Sproule, Beth ; Pollock, Bruce G. ; Mulsant, Benoit H. ; Bies, Robert R. / Clozapine exposure and the impact of smoking and gender : A population pharmacokinetic study. In: Therapeutic Drug Monitoring. 2009 ; Vol. 31, No. 3. pp. 360-366.
@article{437638be73f4427bbeb23b91ef91b2ab,
title = "Clozapine exposure and the impact of smoking and gender: A population pharmacokinetic study",
abstract = "The primary objective of this study was to evaluate the magnitude and variability of concentration exposure to clozapine and norclozapine in a real-world clinical setting, with a focus on smoking status, using population pharmacokinetic methodologies. A retrospective review of plasma clozapine and norclozapine concentrations taken from inpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007 was conducted. A nonlinear mixed-effects model was developed using NONMEM, including age, gender, weight, smoking status, and dosage formulation as covariates. Pharmacokinetic parameters and interindividual and residual variabilities were estimated with 1- and 2-compartment models. A total of 519 plasma clozapine concentrations from 197 patients (138 males; mean ± SD age, 38 ± 13 years; schizophrenia spectrum disorder 98.2{\%}) were included for the analysis. A 1-compartment model with first-order absorption and elimination best described the data. Apparent volume of distribution was fixed to a previously reported value in the literature of 7 L/kg.The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively). For clozapine, smokers and males showed increased oral clearance by 6.0 and 4.5 L/h, respectively. For norclozapine, smokers and male gender were associated with an increased oral clearance of 11.3 and 7.6 L/h, respectively. The formulation of clozapine administered had an impact on the absorption rate with a Ka of 0.14/h for tablet and 10.3/h for the suspension form.The data suggest that smoking and male gender are associated with lower exposure to clozapine and norclozapine due to the higher oral clearance. These findings may account for some of the variability in clozapine exposure and have important implications for individualized drug dosing and therapeutic drug monitoring.",
keywords = "Clozapine, Gender, Nonlinear mixed-effect model, Population pharmacokinetics, Smoking",
author = "Wenzie Ng and Hiroyuki Uchida and Zahinoor Ismail and Mamo, {David C.} and Rajji, {Tarek K.} and Gary Remington and Beth Sproule and Pollock, {Bruce G.} and Mulsant, {Benoit H.} and Bies, {Robert R.}",
year = "2009",
month = "6",
doi = "10.1097/FTD.0b013e31819c7037",
language = "English",
volume = "31",
pages = "360--366",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clozapine exposure and the impact of smoking and gender

T2 - A population pharmacokinetic study

AU - Ng, Wenzie

AU - Uchida, Hiroyuki

AU - Ismail, Zahinoor

AU - Mamo, David C.

AU - Rajji, Tarek K.

AU - Remington, Gary

AU - Sproule, Beth

AU - Pollock, Bruce G.

AU - Mulsant, Benoit H.

AU - Bies, Robert R.

PY - 2009/6

Y1 - 2009/6

N2 - The primary objective of this study was to evaluate the magnitude and variability of concentration exposure to clozapine and norclozapine in a real-world clinical setting, with a focus on smoking status, using population pharmacokinetic methodologies. A retrospective review of plasma clozapine and norclozapine concentrations taken from inpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007 was conducted. A nonlinear mixed-effects model was developed using NONMEM, including age, gender, weight, smoking status, and dosage formulation as covariates. Pharmacokinetic parameters and interindividual and residual variabilities were estimated with 1- and 2-compartment models. A total of 519 plasma clozapine concentrations from 197 patients (138 males; mean ± SD age, 38 ± 13 years; schizophrenia spectrum disorder 98.2%) were included for the analysis. A 1-compartment model with first-order absorption and elimination best described the data. Apparent volume of distribution was fixed to a previously reported value in the literature of 7 L/kg.The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively). For clozapine, smokers and males showed increased oral clearance by 6.0 and 4.5 L/h, respectively. For norclozapine, smokers and male gender were associated with an increased oral clearance of 11.3 and 7.6 L/h, respectively. The formulation of clozapine administered had an impact on the absorption rate with a Ka of 0.14/h for tablet and 10.3/h for the suspension form.The data suggest that smoking and male gender are associated with lower exposure to clozapine and norclozapine due to the higher oral clearance. These findings may account for some of the variability in clozapine exposure and have important implications for individualized drug dosing and therapeutic drug monitoring.

AB - The primary objective of this study was to evaluate the magnitude and variability of concentration exposure to clozapine and norclozapine in a real-world clinical setting, with a focus on smoking status, using population pharmacokinetic methodologies. A retrospective review of plasma clozapine and norclozapine concentrations taken from inpatients at the Centre for Addiction and Mental Health, Toronto, from 2001 to 2007 was conducted. A nonlinear mixed-effects model was developed using NONMEM, including age, gender, weight, smoking status, and dosage formulation as covariates. Pharmacokinetic parameters and interindividual and residual variabilities were estimated with 1- and 2-compartment models. A total of 519 plasma clozapine concentrations from 197 patients (138 males; mean ± SD age, 38 ± 13 years; schizophrenia spectrum disorder 98.2%) were included for the analysis. A 1-compartment model with first-order absorption and elimination best described the data. Apparent volume of distribution was fixed to a previously reported value in the literature of 7 L/kg.The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively). For clozapine, smokers and males showed increased oral clearance by 6.0 and 4.5 L/h, respectively. For norclozapine, smokers and male gender were associated with an increased oral clearance of 11.3 and 7.6 L/h, respectively. The formulation of clozapine administered had an impact on the absorption rate with a Ka of 0.14/h for tablet and 10.3/h for the suspension form.The data suggest that smoking and male gender are associated with lower exposure to clozapine and norclozapine due to the higher oral clearance. These findings may account for some of the variability in clozapine exposure and have important implications for individualized drug dosing and therapeutic drug monitoring.

KW - Clozapine

KW - Gender

KW - Nonlinear mixed-effect model

KW - Population pharmacokinetics

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=67651095921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651095921&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31819c7037

DO - 10.1097/FTD.0b013e31819c7037

M3 - Article

C2 - 19349931

AN - SCOPUS:67651095921

VL - 31

SP - 360

EP - 366

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -